Search

Your search keyword '"C. Godreuil"' showing total 6 results
Start Over Author "C. Godreuil" Topic business
6 results on '"C. Godreuil"'

1. How a specialized cardiogeratric unit can improve Heart failure management: The ICREX-94 experience

Author

Patrick Assayag, K. Richard, G. Billebeau, X. Rovani, J. Shourick, J. Belmin, T. Damy, Jean-Philippe David, C. Godreuil, R. Megbemado, E. Salengro, C. Donadio, N. Rekik, L. Hittinger, E. Berthelot, Amaury Broussier, and S. Cosson

Subjects
medicine.medical_specialty, business.industry, Heart failure, Emergency medicine, Medicine, Context (language use), Cardiology and Cardiovascular Medicine, business, medicine.disease, humanities
Abstract

Context In the context of hospitalization for acute heart failure (AHF), patients’ characteristics and outcome depending on the department of management (cardiologic or cardiogeriatric) are unknown. The aims of this study were to determine the profile and the outcome (rehospitalizations at 90 days) of patients hospitalized for HF in the Val de Marne area, a district in the suburbs of Paris, depending on whether they were hospitalized in cardiology or in a specific cardiogeriatric centre; and to analyze the modes and the precipitating factors triggering rehospitalizations in the two type of centre. Methods We conducted the ICREX-94 observatory within seven French cardiologic departments and three specific cardiogeriatric departments in the Val de Marne district, France. Results 308 patients were hospitalized for AHF between October 2017 and January 2019. During the 3 months following discharge, 52 (17%) patients were rehospitalized for AHF. Compared with patients hospitalized in cardiogeriatric centre, patients from cardiologic department were younger (P Conclusion Compared to cardiogeriatric centres, AHF patients discharged from cardiologic centers had clinical differences, but we found that they had the same prognosis regarding AHF rehospitalization at 90 days.

Published
2021
Full Text
View/download PDF

2. Mort subite du sujet jeune : le défibrillateur sous-cutané S-ICD est-il une solution alternative aux défibrillateurs conventionnels ?

Author

N.-C. Roche, M. Stefuriac, C. Godreuil, L. Bonnevie, N. Dumitrescu, and A. Charbonnel

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Implantable cardioverter-defibrillator, medicine.disease, Sudden cardiac death, Internal medicine, medicine, Cardiology, Lead Dislodgement, New device, Ventricular Perforation, Clinical case, Cardiology and Cardiovascular Medicine, business
Abstract

Implantable cardioverter defibrillator (ICD) is well-recognized therapy to prevent sudden cardiac death. Classic ICD need the use of permanent endocavitary leads, which may cause serious troubles (lead dislodgement, ventricular perforation, lead infections, etc.). The subcutaneous implantable cardioverter defibrillator (S-ICD) is a new device provided by only a subcutaneous lead. It has been developed for the last five years and it is becoming at present a real alternative to classic ICD. We report a clinical case of a 34 y.o. woman who presented a sudden cardiac death and who benefited the implantation of this new technology. This paper deals with the potential indications, usefulness benefits, and problems of the S-ICD.

Published
2015
Full Text
View/download PDF

3. Staphylococcus aureus CC30 Lineage and Absence of sed,j,r-Harboring Plasmid Predict Embolism in Infective Endocarditis

Author

Jean-Philippe Rasigade, Amélie Leclère, François Alla, Adrien Tessier, Michèle Bes, Catherine Lechiche, Véronique Vernet-Garnier, Cédric Laouénan, François Vandenesch, Catherine Leport, The AEPEI Study Group, B. Hoen, X. Duval, F. Alla, A. Bouvet, S. Briancxon, E. Cambau, M. Celard, C. Chirouze, N. Danchin, T. Doco-Lecompte, F. Delahaye, J. Etienne, B. Iung, V. Le Moing, J. F. Obadia, C. Leport, C. Poyart, M. Revest, C. Selton-Suty, C. Strady, P. Tattevin, F. Vandenesch, Y. Bernard, S. Chocron, P. Plesiat, I. Abouliatim, C. De Place, P. Y. Donnio, J. P. Carteaux, C. Lion, N. Aissa, B. Baehrel, R. Jaussaud, P. Nazeyrollas, V. Vernet, P. Nataf, C. Chidiac, H. Aumaître, J. M. Frappier, E. Oziol, A. Sotto, C. Sportouch, M. Bes, P. Abassade, E. Abrial, C. Acar, J. F. Alexandra, N. Amireche, D. Amrein, P. Andre, M. Appriou, M. A. Arnould, P. Assayag, A. Atoui, F. Aziza, N. Baille, N. Bajolle, P. Battistella, S. Baumard, A. Ben Ali, J. Bertrand, S. Bialek, M. Bois Grosse, M. Boixados, F. Borlot, A. Bouchachi, O. Bouche, S. Bouchemal, J. L. Bourdon, L. Brasme, F. Bricaire, E. Brochet, F. J. Bruntz, A. Cady, J. Cailhol, M. P. Caplan, B. Carette, O. Cartry, C. Cazorla, H. Chamagne, H. Champagne, G. Chanques, J. Chastre, B. Chevalier, F. Chometon, C. Christophe, A. Cohen, N. Colin de Verdiere, V. Daneluzzi, L. David, P. De Lentdecker, V. Delcey, P. Deleuze, E. Donal, B. Deroure, V. Descotes-Genon, K. Didier Petit, A. Dinh, V. Doat, F. Duchene, F. Duhoux, M. Dupont, S. Ederhy, O. Epaulard, M. Evest, J. F. Faucher, B. Fantin, E. Fauveau, T. Ferry, M. Fillod, T. Floch, T. Fraisse, J. M. Frapier, L. Freysz, B. Fumery, B. Gachot, S. Gallien, I. Gandjbach, P. Garcon, A. Gaubert, J. L. Genoud, S. Ghiglione, C. Godreuil, A. Grentzinger, L. Groben, D. Gherissi, P. Gue'ret, A. Hagege, N. Hammoudi, F. Heliot, P. Henry, S. Herson, P. Houriez, L. Hustache-Mathieu, O. Huttin, S. Imbert, S. Jaureguiberry, M. Kaaki, A. Konate, J. M. Kuhn, S. Kural Menasche, A. Lafitte, B. Lafon, F. Lanternier, V. Le Chenault, C. Lechiche, S. Lefèvre-Thibaut, A. Lefort, A. Leguerrier, J. Lemoine, L. Lepage, C. Lepouse', J. Leroy, P. Lesprit, L. Letranchant, D. Loisance, G. Loncar, C. Lorentz, P. Mabo, I. Magnin-Poull, T. May, A. Makinson, H. Man, M. Mansouri, O. Marcxon, J. P. Maroni, V. Masse, F. Maurier, M. C. Meyohas, P. L. Michel, C. Michelet, F. Mechaï, O. Merceron, D. Messika-Zeitoun, Z. Metref, V. Meyssonnier, C. Mezher, S. Micheli, M. Monsigny, S. Mouly, B. Mourvillier, O. Nallet, V. Noel, T. Papo, B. Payet, A. Pelletier, P. Perez, J. S. Petit, F. Philippart, E. Piet, C. Plainvert, B. Popovic, J. M. Porte, P. Pradier, R. Ramadan, J. Richemond, M. Rodermann, M. Roncato, I. Roigt, O. Ruyer, M. Saada, J. Schwartz, M. Simon, B. Simorre, S. Skalli, F. Spatz, J. Sudrial, L. Tartiere, A. Terrier De La Chaise, M. C. Thiercelin, D. Thomas, M. Thomas, L. Toko, F. Tournoux, A. Tristan, J. L. Trouillet, L. Tual, A. Vahanian, F. Verdier, V. Vernet Garnier, V. Vidal, P. Weyne, M. Wolff, A. Wynckel, N. Zannad, P. Y. Zinzius, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis (StaPath), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de Reference des Staphylocoques, Université de Lyon, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Service des maladies infectieuses et tropicales, Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Entérobactéries Résistance Acquise - EA 4687 (ERA), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)

Subjects
0301 basic medicine, Microbiology (medical), Immunology, lcsh:QR1-502, MRSA, medicine.disease_cause, Staphylococcal infections, Microbiology, lcsh:Microbiology, superantigen, 03 medical and health sciences, plasmid, medicine, Endocarditis, business.industry, infective endocarditis, SCCmec, Odds ratio, medicine.disease, S. aureus, Methicillin-resistant Staphylococcus aureus, stroke, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, 030104 developmental biology, Infectious Diseases, Embolism, Staphylococcus aureus, Infective endocarditis, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, CC30, [SDV.IMM]Life Sciences [q-bio]/Immunology, business, enterotoxin
Abstract

International audience; Staphylococcus aureus induces severe infective endocarditis (IE) where embolic complications are a major cause of death. Risk factors for embolism have been reported such as a younger age or larger IE vegetations, while methicillin resistance conferred by the mecA gene appeared as a protective factor. It is unclear, however, whether embolism is influenced by other S. aureus characteristics such as clonal complex (CC) or virulence pattern. We examined clinical and microbiological predictors of embolism in a prospective multicentric cohort of 98 French patients with monomicrobial S. aureus IE. The genomic contents of causative isolates were characterized using DNA array. To preserve statistical power, genotypic predictors were restricted to CC, secreted virulence factors and virulence regulators. Multivariate regularized logistic regression identified three independent predictors of embolism. Patients at higher risk were younger than the cohort median age of 62.5 y (adjusted odds ratio [OR] 0.14; 95% confidence interval [CI] 0.05-0.36). S. aureus characteristics predicting embolism were a CC30 genetic background (adjusted OR 9.734; 95% CI 1.53-192.8) and the absence of pIB485-like plasmid-borne enterotoxin-encoding genes sed, sej, and ser (sedjr; adjusted OR 0.07; 95% CI 0.004-0.457). CC30 S. aureus has been repeatedly reported to exhibit enhanced fitness in bloodstream infections, which might impact its ability to cause embolism. sedjr-encoded enterotoxins, whose superantigenic activity is unlikely to protect against embolism, possibly acted as a proxy to others genes of the pIB485-like plasmid found in genetically unrelated isolates from mostly embolism-free patients. mecA did not independently predict embolism but was strongly associated with sedjr. This mecA-sedjr association might have driven previous reports of a negative association of mecA and embolism. Collectively, our results suggest that the influence of S. aureus genotypic features on the risk of embolism may be stronger than previously suspected and independent of clinical risk factors.

Published
2018
Full Text
View/download PDF

4. Péricardite aiguë et prétamponnade : un mode de révélation atypique d’une tuberculose viscérale

Author

N.-C. Roche, D. Andriamanantena, C. Flateau, N. Dumitrescu, J. Lupu, Cécile Ficko, M. Stefuriac, O. Thabouillot, A. Charbonnel, F. Bouvier, C. Rapp, and C. Godreuil

Subjects
Social risk, Pediatrics, medicine.medical_specialty, Tuberculosis, business.industry, Pulmonary disease, medicine.disease, Pericardial effusion, Pericarditis, Cardiac tamponade, Medicine, Medical history, Cardiology and Cardiovascular Medicine, business
Abstract

Tuberculosis is a common pulmonary disease, which is still endemic in disadvantaged communities. Pericarditis is a rare but very lethal visceral localization. The authors report the case of a 58-year-old man, without neither medical history nor social risk, who presented a cardiac tamponade as the first and atypic manifestation of a visceral tuberculosis.

Published
2015
Full Text
View/download PDF

5. Douleurs thoraciques, dyspnée et crachats hémoptoïques chez un ancien toxicomane

Author

R. Juglard, J. Margery, A. Gervaise, E. Henninot, D. Dorléac, C. Godreuil, A. Girodeau, and J.M. Dot

Subjects
Pulmonary and Respiratory Medicine, Gynecology, medicine.medical_specialty, Tricuspid valve, Serratia infection, biology, business.industry, Staphyloccocus aureus, medicine.disease_cause, medicine.disease, Staphylococcal infections, biology.organism_classification, Pulmonary embolism, medicine.anatomical_structure, Staphylococcus aureus, Serratia marcescens, medicine, business
Abstract

Resume A l’occasion d’une embolie pulmonaire septique, une endocardite tricuspidienne a Staphyloccocus aureus et Serratia marcescens est decouverte chez un ancien toxicomane. Malgreune antibiotherapie systemique adaptee, la persistance d’une vegetation supracentrimetrique et l’aggravation de complications immunologiques renales font pratiquer une chirurgie conservatrice de l’orifice tricuspidien. L’evolution est rapidement favorable et permet la reprise des activites habituelles.

Published
2007
Full Text
View/download PDF

6. Choc vasoplégique et infarctus du myocarde lors de l’administration d’iloprost

Author

C. Godreuil, Roland Carlioz, Gilles Quiniou, Eric Perrier, S. Geffroy, and É. Naoum

Subjects
Gynecology, medicine.medical_specialty, business.industry, Shock (circulatory), medicine, General Medicine, medicine.symptom, Myocardial disease, business
Abstract

Resume Introduction L’association d’un choc vasoplegique et d’un infarctus du myocarde chez un patient traite par iloprost pour ischemie critique des membres inferieurs n’a pas ete rapportee jusqu’alors. Observation Chez un patient âge de 56 ans, diabetique de type 2, hypertendu et dyslipidemique, une ischemie critique du membre inferieur droit a ete traitee par iloprost. Au 19th jour de perfusion, est survenu un etat de choc avec infarctus du myocarde, d’evolution secondairement favorable. Commentaires Cette observation implique un renforcement de la surveillance de la pression arterielle ainsi que de l’electrocardiogramme chez des patients diabetiques traites par iloprost.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results